“Every community is unique,” says Ruth Rechis, Ph.D., director of Be Well Communities™, MD Anderson’s place-based strategy for cancer prevention and control.
Building on MD Anderson’s decades at the forefront of cancer prevention research, Be Well Communities uses best practices to deploy science-based cancer prevention strategies to communities with the greatest need. It brings individuals and organizations...
Scientific discoveries are essential to driving advances in cancer care. From better screening and diagnostic techniques to innovative new...
Since the discovery of KRAS gene mutations in 1983, researchers have worked to develop new therapies that target this protein when treating...
B-cell lymphoma isn’t one disease. There are about 63 subtypes, with diffuse large B-cell lymphoma (DLBCL) being the most common. A chemotherapy regimen called R-CHOP has been the standard treatment approach since 2002, when the antibody therapy rituximab was added to the chemotherapy regimen CHOP.
Almost 60% of patients find success with R-CHOP. But what about the
remaining 40% of B-cell lymphoma patients?
“The success...
Last updated Jan. 11, 2022.
First emerging almost three decades ago, monoclonal antibodies are changing the way doctors treat cancer...
In the last decade, immunotherapy has become a viable treatment option for many cancer patients. Unlike radiation and chemotherapy, immunotherapy...
After completing a course of treatment, there are few words that sound better to a patient than “complete remission.” It’s an indication that...
Natural killer cells – or NK cells – are part of our immune system. They patrol our bodies for abnormal cells like cancer and destroy them...
Lori Shults didn’t know much about clinical trials when she first came to MD Anderson in May 2017. “I thought they involved some people getting...
MD Anderson’s Moon Shots Program™ increases the speed at which our experts turn their research into new cancer treatment options for patients...